 Home > Active Ingredient News > Antitumor Therapy > Hepatology: Dynamic risk prediction of recurrence after radical hepatectomy for hepatocellular carcinoma

Hepatology: Dynamic risk prediction of recurrence after radical hepatectomy for hepatocellular carcinoma

 Last Update: 2022-03-05
 Source: Internet
 Author: User

Tags

1 2 dichlorobutane

al 3

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

After radical liver resection (LR) in patients with hepatocellular carcinoma (HCC), the likelihood of survival is dynamic because multiple recurrences and/or metastases may occur, and the impact of each recurrence/metastasis on patient outcomes are all different
.

This study aimed to use a multi-state model to assess the natural progression, patterns, and timing of various disease states after hepatectomy and to develop a practical algorithm to provide patients and clinicians with predictive information about their prognosis
.

The distribution of the number of patients in different states

We retrospectively identified adult patients who underwent liver resection for hepatocellular carcinoma at a single medical center between January 2000 and December 2018
.

Multistate analysis models tumor progression after hepatectomy by describing transitions between different disease states

Subsequent local recurrence-free survival in patients with different status

A total of 486 patients were included, of which 169 (34.
8%) remained recurrence-free, 205 (42.
2%) developed intrahepatic recurrence, 80 (16.
5%) developed distant metastases, and 32 (7%) has died
.

For the average patient undergoing liver resection, the odds of remaining disease-free within the first 60 months after surgery were 33.

169 (34.

Compared with standard single-event time-to-event estimates, multi-state modeling provides more realistic predictions and criteria for clinical outcomes after hepatectomy for patients with hepatocellular carcinoma by accounting for multiple postoperative disease states and transitions between them.

Original source:

Ivanics Tommy, Murillo Perez Carla Fiorella, Claasen Marco Paw et al.

Dynamic risk profiling of hepatocellular carcinoma recurrence after curative intent liver resectionLeave a comment here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Bulk Peptides Kisspeptin 10 (human) /Kisspeptin 10/ Kisspeptin-10 Acetate CAS 374675-21-5

CAS No.: 374675-21-5

Pharmacy Grade

$10-13/UNIT FOB

Cediranib

CAS No.: 288383-20-0

$22/KG EXW

Upadacitinib hemihydrate API

CAS No.: 2050057-56-0

Pharmacy Grade

$35-45/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.